Lily AI vs Kenvue

Side-by-side comparison of AI visibility scores, market position, and capabilities

Kenvue leads in AI visibility (94 vs 70)
Lily AI logo

Lily AI

ChallengerRetail Tech

Product Attribute AI & Catalog Enrichment

Product attribute AI platform for retail. Founded 2015, Mountain View CA. Raised $52.4M. Drives 8-9 figure revenue uplift for fashion, home, and beauty retailers. Private.

AI VisibilityBeta
Overall Score
B70
Category Rank
#1 of 1
AI Consensus
78%
Trend
up
Per Platform
ChatGPT
81
Perplexity
77
Gemini
78

About

Lily AI is a product intelligence platform founded in 2015 by Purva Gupta (CEO) and Sowmiya Chocka Narayanan, headquartered in Mountain View, California. The company uses AI to automatically generate rich, consumer-centric product attributes for retail catalogs across fashion, home, and beauty verticals, transforming merchant-speak descriptions into the language customers actually use when searching.

Full profile
Kenvue logo

Kenvue

LeaderConsumer Goods

Enterprise

Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.

AI VisibilityBeta
Overall Score
A94
Category Rank
#31 of 290
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
91
Perplexity
99
Gemini
89

About

Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).

Full profile

AI Visibility Head-to-Head

70
Overall Score
94
#1
Category Rank
#31
78
AI Consensus
70
up
Trend
stable
81
ChatGPT
91
77
Perplexity
99
78
Gemini
89
71
Claude
93
76
Grok
86

Key Details

Category
Product Attribute AI & Catalog Enrichment
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Lily AI
Product Attribute AI & Catalog Enrichment

Integrations

Kenvue is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.